USA Financial Formulas Makes New $919,000 Investment in Bristol Myers Squibb Company $BMY

USA Financial Formulas bought a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,923 shares of the biopharmaceutical company’s stock, valued at approximately $919,000.

Several other institutional investors and hedge funds have also modified their holdings of BMY. Aull & Monroe Investment Management Corp boosted its holdings in Bristol Myers Squibb by 3.3% in the 3rd quarter. Aull & Monroe Investment Management Corp now owns 9,514 shares of the biopharmaceutical company’s stock valued at $594,000 after purchasing an additional 300 shares during the period. Kintegral Advisory LLC grew its position in shares of Bristol Myers Squibb by 3.9% during the 3rd quarter. Kintegral Advisory LLC now owns 120,605 shares of the biopharmaceutical company’s stock worth $7,526,000 after purchasing an additional 4,494 shares in the last quarter. New England Research & Management Inc. bought a new position in shares of Bristol Myers Squibb during the third quarter worth approximately $1,945,000. Intergy Private Wealth LLC bought a new position in shares of Bristol Myers Squibb during the third quarter worth approximately $227,000. Finally, Avail Investment Partners LLC raised its position in shares of Bristol Myers Squibb by 12.4% in the third quarter. Avail Investment Partners LLC now owns 10,953 shares of the biopharmaceutical company’s stock valued at $683,000 after buying an additional 1,207 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
• Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb’s Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
• Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Analysts Set New Price Targets

Several equities research analysts recently issued reports on BMY shares. Zacks Research upgraded Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 23rd. Argus raised Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a research report on Wednesday, August 5th. Guggenheim restated a “buy” rating and set a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. TD Cowen began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating for the company. Finally, Rothschild & Co Redburn lifted their price objective on Bristol Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $64.88.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Trading Down 1.4%

BMY opened at $59.69 on Friday. The stock has a market capitalization of $121.94 billion, a price-to-earnings ratio of 13.15, a P/E/G ratio of 0.30 and a beta of 0.19. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The company has a 50-day simple moving average of $63.55 and a 200 day simple moving average of $60.29.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period last year, the firm earned $1.46 EPS. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.56 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.